BICX - BioCorRx starts recruiting in trial of biodegradable naltrexone pellet BICX104 for opioid disorder

BioCorRx (OTCQB:BICX) said it began the recruiting and enrollment process for its first-in-human trial of BICX104, an implantable biodegradable naltrexone pellet to treat opioid use disorder (OUD). The phase 1 study will be in two parallel groups of randomized healthy volunteers to evaluate the pharmacokinetics and safety of BICX104 implantable subcutaneous naltrexone pellets and the marketed once a month intramuscular depot naltrexone injection. The company said BICX104 is being developed in collaboration with the National Institute on Drug Abuse, part of the National Institutes of Health.

For further details see:

BioCorRx starts recruiting in trial of biodegradable naltrexone pellet BICX104 for opioid disorder